TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
Brief Summary: The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: Part 1 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Part 2 - Etanercept and nbUVB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Device: nbUVB | Arm Label: Part 2 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Part 1 - Etanercept, Part 2 - Etanercept, Part 2 - Etanercept and nbUVB | Intervention Type: DEVICE; Name: nbUVB; Assigned to Arm(s): Part 2 - Etanercept and nbUVB
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
Brief Summary: The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control
B: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
C: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
D: Arm Label: Secukinumab 150mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150 mg s.c. | Arm Label: Secukinumab 300mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg s.c. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab 150 mg s.c.; Assigned to Arm(s): Secukinumab 150mg | Intervention Type: DRUG; Name: Secukinumab 300 mg s.c.; Assigned to Arm(s): Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
Brief Summary: Patients undergoing semi-elective lower extremity major amputation from complications associated with atherosclerotic limb ischemia will received intra-muscular injections of allogeneic Mesenchymal Stromal Cells in the leg above and below the point of amputation to prevent ischemic wound complications after surgery and decrease the incidence of revision and further amputation. Cohort Groups 1-4 will serve as controls.


Options:
A: Arm Label: Active/Treatment Group; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic bone marrow derived mesenchymal stem cells | Arm Label: Observation Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 3; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Group 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Allogeneic bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Active/Treatment Group
B: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: CD34-positive cells | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: CD34-positive cells | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline and 5% autologous plasma | Intervention Type: BIOLOGICAL; Name: CD34-positive cells; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: CD34-positive cells; Assigned to Arm(s): High Dose | Intervention Type: BIOLOGICAL; Name: Saline and 5% autologous plasma; Assigned to Arm(s): Saline
C: Arm Label: ALD-301; Type: EXPERIMENTAL; Interventions: Biological: ALD-301 | Arm Label: Placebo (vehicle); Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (vehicle) | Intervention Type: BIOLOGICAL; Name: ALD-301; Assigned to Arm(s): ALD-301 | Intervention Type: BIOLOGICAL; Name: Placebo (vehicle); Assigned to Arm(s): Placebo (vehicle)
D: Arm Label: Autologous Bone Marrow Mononuclear Cells; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells; Assigned to Arm(s): Autologous Bone Marrow Mononuclear Cells

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
Brief Summary: Patients undergoing semi-elective lower extremity major amputation from complications associated with atherosclerotic limb ischemia will received intra-muscular injections of allogeneic Mesenchymal Stromal Cells in the leg above and below the point of amputation to prevent ischemic wound complications after surgery and decrease the incidence of revision and further amputation. Cohort Groups 1-4 will serve as controls.


Options:
A: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: Bone marrow punction, Procedure: BM-MNC infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Bone marrow punction, Procedure: Placebo infusion | Intervention Type: PROCEDURE; Name: Bone marrow punction; Assigned to Arm(s): BM-MNC, Placebo | Intervention Type: PROCEDURE; Name: BM-MNC infusion; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: Placebo infusion; Assigned to Arm(s): Placebo
B: Arm Label: mesenchymal stem cells; Type: EXPERIMENTAL; Interventions: Drug: mesenchymal stem cells | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Plasmalyte A | Intervention Type: DRUG; Name: mesenchymal stem cells; Assigned to Arm(s): mesenchymal stem cells | Intervention Type: DRUG; Name: Plasmalyte A; Assigned to Arm(s): Placebo
C: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection
D: Arm Label: Active/Treatment Group; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic bone marrow derived mesenchymal stem cells | Arm Label: Observation Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 3; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Group 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Allogeneic bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Active/Treatment Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Collaborative Assessment and Management of Suicidality" (CAMS) in Comparison to "Treatment as Usual" (TAU) for Suicidal Patients: a Randomized Controlled Trial
Brief Summary: Although suicide risk is highly prevalent among the patient population in mental health care, remarkably little research exists on effective treatments. Among a small set of novel approaches, CAMS is particularly promising. The investigators compare CAMS to TAU in a randomized controlled trial at four departments in Vestre Viken Hospital Trust, hypothesizing CAMS to be the superior approach. Primary outcome measures are suicidal ideation and suicide attempts, with secondary outcome measures including general symptoms of mental health problems. Changes in the outcome measures are compared between the two groups from baseline to 6 and 12 months after patients are included in the study. The study has the potential to impact the science of treating suicidal individuals and it could benefit the general public by establishing CAMS as an effective clinical approach for rapidly reducing suicide risk.


Options:
A: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
B: Arm Label: Standard DBT + PTSD Protocol; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behavior Therapy, Behavioral: PTSD Protocol | Arm Label: Standard DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Standard DBT, Standard DBT + PTSD Protocol | Intervention Type: BEHAVIORAL; Name: PTSD Protocol; Assigned to Arm(s): Standard DBT + PTSD Protocol
C: Arm Label: Commitment; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Skills Training | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT Skills Training | Intervention Type: BEHAVIORAL; Name: DBT Skills Training; Assigned to Arm(s): Commitment, Psychoeducation
D: Arm Label: VHS group; Type: EXPERIMENTAL; Interventions: Behavioral: the volitional help sheet | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: the volitional help sheet; Assigned to Arm(s): VHS group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Collaborative Assessment and Management of Suicidality" (CAMS) in Comparison to "Treatment as Usual" (TAU) for Suicidal Patients: a Randomized Controlled Trial
Brief Summary: Although suicide risk is highly prevalent among the patient population in mental health care, remarkably little research exists on effective treatments. Among a small set of novel approaches, CAMS is particularly promising. The investigators compare CAMS to TAU in a randomized controlled trial at four departments in Vestre Viken Hospital Trust, hypothesizing CAMS to be the superior approach. Primary outcome measures are suicidal ideation and suicide attempts, with secondary outcome measures including general symptoms of mental health problems. Changes in the outcome measures are compared between the two groups from baseline to 6 and 12 months after patients are included in the study. The study has the potential to impact the science of treating suicidal individuals and it could benefit the general public by establishing CAMS as an effective clinical approach for rapidly reducing suicide risk.


Options:
A: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
B: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
C: Arm Label: Short-term MBT; Type: EXPERIMENTAL; Interventions: Other: Short-term MBT | Arm Label: Long-term MBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Long-term MBT | Intervention Type: OTHER; Name: Short-term MBT; Assigned to Arm(s): Short-term MBT | Intervention Type: OTHER; Name: Long-term MBT; Assigned to Arm(s): Long-term MBT
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Collaborative Assessment and Management of Suicidality" (CAMS) in Comparison to "Treatment as Usual" (TAU) for Suicidal Patients: a Randomized Controlled Trial
Brief Summary: Although suicide risk is highly prevalent among the patient population in mental health care, remarkably little research exists on effective treatments. Among a small set of novel approaches, CAMS is particularly promising. The investigators compare CAMS to TAU in a randomized controlled trial at four departments in Vestre Viken Hospital Trust, hypothesizing CAMS to be the superior approach. Primary outcome measures are suicidal ideation and suicide attempts, with secondary outcome measures including general symptoms of mental health problems. Changes in the outcome measures are compared between the two groups from baseline to 6 and 12 months after patients are included in the study. The study has the potential to impact the science of treating suicidal individuals and it could benefit the general public by establishing CAMS as an effective clinical approach for rapidly reducing suicide risk.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
B: Arm Label: Study participants; Type: EXPERIMENTAL; Interventions: Other: EMA | Intervention Type: OTHER; Name: EMA; Assigned to Arm(s): Study participants
C: Arm Label: TAU w/ mobile app + volunteer support; Type: EXPERIMENTAL; Interventions: Behavioral: Volunteer support, Other: Mobile app | Arm Label: TAU w/ mobile app engagement; Type: EXPERIMENTAL; Interventions: Other: Mobile app | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Volunteer support; Assigned to Arm(s): TAU w/ mobile app + volunteer support | Intervention Type: OTHER; Name: Mobile app; Assigned to Arm(s): TAU w/ mobile app + volunteer support, TAU w/ mobile app engagement
D: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Collaborative Assessment and Management of Suicidality" (CAMS) in Comparison to "Treatment as Usual" (TAU) for Suicidal Patients: a Randomized Controlled Trial
Brief Summary: Although suicide risk is highly prevalent among the patient population in mental health care, remarkably little research exists on effective treatments. Among a small set of novel approaches, CAMS is particularly promising. The investigators compare CAMS to TAU in a randomized controlled trial at four departments in Vestre Viken Hospital Trust, hypothesizing CAMS to be the superior approach. Primary outcome measures are suicidal ideation and suicide attempts, with secondary outcome measures including general symptoms of mental health problems. Changes in the outcome measures are compared between the two groups from baseline to 6 and 12 months after patients are included in the study. The study has the potential to impact the science of treating suicidal individuals and it could benefit the general public by establishing CAMS as an effective clinical approach for rapidly reducing suicide risk.


Options:
A: Arm Label: PS CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Problem solving cognitive behaviour therapy (PS CBT) | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Problem solving cognitive behaviour therapy (PS CBT); Assigned to Arm(s): PS CBT
B: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
C: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
D: Arm Label: Dialectical Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Inidividual and Group Supportive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual and Group Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy | Intervention Type: BEHAVIORAL; Name: Individual and Group Supportive Therapy; Assigned to Arm(s): Inidividual and Group Supportive Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Collaborative Assessment and Management of Suicidality" (CAMS) in Comparison to "Treatment as Usual" (TAU) for Suicidal Patients: a Randomized Controlled Trial
Brief Summary: Although suicide risk is highly prevalent among the patient population in mental health care, remarkably little research exists on effective treatments. Among a small set of novel approaches, CAMS is particularly promising. The investigators compare CAMS to TAU in a randomized controlled trial at four departments in Vestre Viken Hospital Trust, hypothesizing CAMS to be the superior approach. Primary outcome measures are suicidal ideation and suicide attempts, with secondary outcome measures including general symptoms of mental health problems. Changes in the outcome measures are compared between the two groups from baseline to 6 and 12 months after patients are included in the study. The study has the potential to impact the science of treating suicidal individuals and it could benefit the general public by establishing CAMS as an effective clinical approach for rapidly reducing suicide risk.


Options:
A: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
B: Arm Label: SB-APP Psychotherapy; Type: EXPERIMENTAL; Interventions: Other: SB-APP | Arm Label: TAU treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: SB-APP; Assigned to Arm(s): SB-APP Psychotherapy | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): TAU treatment
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group 1, Group 2
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Psychiatric Management | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Intervention Type: BEHAVIORAL; Name: General Psychiatric Management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): 2

Answer: A